Cipla Limited (CIPLA) — Financial Results | 28 January 2025(3 announcements)

· NSE 🔴 High Importance Neutral
By StockFin Research Team AI-Assisted Analysis Source: BSE/NSE Filings
1 Financial Results 🔴 High Importance Neutral 📄 PDF

Cipla reported unaudited consolidated revenue of ₹7,072.97 crores for Q3 FY2025, up 32% YoY, with net profit at ₹1,574.59 crores, reflecting strong growth in pharmaceutical sales and new ventures. The Board approved results on 28 January 2025, highlighting operational momentum and strategic progress in discontinuing legacy businesses.

2 Financial Results 🔴 High Importance Neutral 📄 PDF

Cipla reported consolidated revenue of ₹7,073 crores for Q3 FY25, an 8% YoY increase, with EBITDA margin expanding to 28.1% and PAT rising 49.7% YoY to INR 1,571 crores, driven by growth across all geographies and improved operational efficiency.

3 Financial Results 🔴 High Importance Neutral 📄 PDF

Cipla reported consolidated net profit of ₹1,574.59 crore for Q3 FY2024, up 69.9% YoY, driven by revenue of ₹7,072.97 crore. The company faces NPPA demands of ₹2,011 crore but expects favorable resolution without provisioning. Tax provisions reversed by ₹155.61 crore due to ITAT orders. Paid-up capital rose to ₹161.52 crore post-share issuances. The Generics Business transferred to CPLS on February 29, 2024.

About Cipla Limited (CIPLA)

Healthcare · Pharmaceuticals & Biotechnology · Listed on NSE

Market Cap: ₹1,15,682.55 Cr P/E: 25.4 ROE: 14.6% ROCE: 19.4%

View full CIPLA stock details →

📡 Get AI alerts when CIPLA files next

Free • Daily 5 PM digest • Track filings, board meetings, and corporate actions

Track CIPLA — Free

📊 More CIPLA filings

See all CIPLA filings →

Source: Stock Announcements. Analysis by StockFin.ai. For informational purposes only — not investment advice.

Editorial & Data Transparency Notice

This analysis was programmatically compiled using StockFin AI utilizing official regulatory disclosures from the BSE and NSE. Content is automatically synthesized and audited against public financial filings. StockFin.ai is an educational research platform and is NOT a SEBI-registered investment advisor or research analyst.

📡 Get AI alerts when CIPLA files new disclosures

Track CIPLA filings, board meetings, and corporate actions. Free email alerts at 5 PM.

Track CIPLA — Free

Free account · 2 AI queries/day